argenx (NASDAQ:ARGX) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

argenx (NASDAQ:ARGX - Free Report) had its price objective upped by Wells Fargo & Company from $723.00 to $741.00 in a research report sent to investors on Friday,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the stock.

A number of other equities analysts also recently commented on ARGX. Deutsche Bank Aktiengesellschaft downgraded shares of argenx from a "hold" rating to a "sell" rating in a report on Friday, January 17th. Scotiabank raised argenx from a "sector perform" rating to a "sector outperform" rating and lifted their price objective for the company from $439.00 to $715.00 in a report on Tuesday, November 5th. HC Wainwright increased their target price on argenx from $717.00 to $720.00 and gave the stock a "buy" rating in a report on Friday. Oppenheimer boosted their price target on argenx from $675.00 to $704.00 and gave the company an "outperform" rating in a research note on Friday. Finally, JPMorgan Chase & Co. increased their price objective on argenx from $640.00 to $670.00 and gave the stock an "overweight" rating in a research note on Monday, November 4th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $662.83.

Remove Ads

argenx Trading Down 0.2 %

ARGX traded down $1.36 on Friday, hitting $621.25. 285,887 shares of the stock traded hands, compared to its average volume of 273,997. The business has a fifty day moving average price of $642.51 and a two-hundred day moving average price of $591.91. argenx has a 52 week low of $349.86 and a 52 week high of $678.21. The firm has a market capitalization of $37.75 billion, a PE ratio of -705.97 and a beta of 0.58.

argenx (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, beating analysts' consensus estimates of $0.98 by $0.60. The business had revenue of $761.22 million during the quarter, compared to analyst estimates of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. On average, equities research analysts forecast that argenx will post 3.13 EPS for the current fiscal year.

Hedge Funds Weigh In On argenx

Several large investors have recently made changes to their positions in the company. Stifel Financial Corp raised its holdings in argenx by 15.3% during the 3rd quarter. Stifel Financial Corp now owns 8,832 shares of the company's stock worth $4,788,000 after purchasing an additional 1,170 shares during the last quarter. FMR LLC raised its stake in shares of argenx by 35.9% during the third quarter. FMR LLC now owns 4,793,472 shares of the company's stock worth $2,598,445,000 after buying an additional 1,265,486 shares during the last quarter. Simplify Asset Management Inc. lifted its holdings in argenx by 64.0% in the third quarter. Simplify Asset Management Inc. now owns 2,419 shares of the company's stock valued at $1,311,000 after buying an additional 944 shares during the period. Stephens Inc. AR bought a new position in argenx in the fourth quarter valued at approximately $310,000. Finally, Ritholtz Wealth Management grew its holdings in argenx by 85.5% during the 4th quarter. Ritholtz Wealth Management now owns 898 shares of the company's stock worth $552,000 after acquiring an additional 414 shares during the period. Institutional investors and hedge funds own 60.32% of the company's stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.